机构:[1]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.河北医科大学第四医院[2]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang, China.[3]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.河北医科大学第四医院[4]Radiotherapy Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.河北医科大学第四医院
This research was funded by Natural Science Foundation of Hebei Province, No.
H2023206441 and Beijing-Tianjin-Hebei Basic Research Cooperation Project,
No. J230016.
第一作者机构:[1]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.[2]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang, China.
共同第一作者:
通讯作者:
通讯机构:[1]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.[2]Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang, China.[*1]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
推荐引用方式(GB/T 7714):
Wu Shang,Ma Xin-Di,Zhang Xiang-Mei,et al.Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER- breast cancer: A Mendelian randomization study[J].Medicine.2024,103(43):e40262.doi:10.1097/MD.0000000000040262.
APA:
Wu Shang,Ma Xin-Di,Zhang Xiang-Mei,Shi Chao,Du Kai-Ye&Liu Yun-Jiang.(2024).Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER- breast cancer: A Mendelian randomization study.Medicine,103,(43)
MLA:
Wu Shang,et al."Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER- breast cancer: A Mendelian randomization study".Medicine 103..43(2024):e40262